← Back to patent-cliff list
Zolmitriptan
Tier C — Watch / tradeZolmitriptan
AstraZeneca
Originator
1997
First approval
-
Expiry (public)
$0.45B ▲
Peak sales
Small molecule
Type
Targets：5-HT1B, 5-HT1A, 5-HT1D
Brand：Zolmitriptan RapidFilm, Zomigon, Flezol, Zomig, AscoTop
Indications (approved)：Migraine
Regional status
US
Withdrawn
EU
Approved
1997-03-01
China
Approved
1999-03-12
Japan
Approved
2001-06-20
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Zolmitriptan?
Approved indications include: Migraine.
When does the Zolmitriptan patent expire?
No public expiry year is available for Zolmitriptan yet; this page updates once verified.
How do I get a quote for Zolmitriptan intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27